Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer
Prabhakar Pitta Venkata(Unknown), Gangadhara R. Sareddy(The University of Texas at San Antonio Health Science Center)
Cited by 18
Related Papers
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma
|Scientific Reports|2016|71
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer
|Cancer Letters|2021|19